Complete Conference Coverage Archive
One instance of grade 3 alanine aminotransferase elevation and 5 instances of reversible immune-related adverse events were observed.
Improvement in RFS was seen regardless of PD-L1 status.
Researchers infected various tumor cell lines with anti-rotavirus vaccines confirmed to be PRR agonists.
At surgery, blood samples were taken from 163 patients; whole genome sequencing and whole exome signaling were performed on detected CTCs.
Mice treated with 2-94 had few or no signs of lymphopenia or neutropenia, common adverse events associated with palbociclib.
Antigen-specific T cells increased in frequency in vaccinated mice.
Per-cycle, PLD cost $2509, bevacizumab cost $7585, and pembrolizumab cost $9026.
After the initial year of follow-up, 2 patients in the standard arm and 1 patient in the re-curettage arm had relapsed.
p53 mutational status may be a viable strategy upon which to base the course of therapy.
There were no significant differences in patterns of recurrence in the chemotherapy vs CCRT groups.
Nearly half of patients were denied insurance coverage for a recommended treatment.
Toxicity was similar in both arms.
Patients in the single-course MTX+ACTD arm had a 46.81% CR rate after initial therapy.
Researchers randomly assigned 120 patients to receive bupivacaine HCl or liposomal bupivacaine.
Overall, 257 vs 527 SLNs were detected by isosulfan blue vs ICG, respectively.
There were no reported changes in pain scores after surgery.
Researchers randomly assigned 74 patients to receive everolimus plus letrozole daily or tamoxifen daily plus medroxyprogesterone daily on alternating weeks.
The impact of the ACA on health insurance access among women diagnosed with a gynecologic cancer was previously unestablished.
In separate studies, apalutamide, an investigational agent, and enzalutamide prolonged metastasis-free survival in men with non-metastatic castration-resistant prostate cancer.
Findings from the phase 2 CABOSUN study showed that, compared with sunitinib, cabozantinib improves PFS and the ORR among patients with advanced RCC.
The impact of this treatment on quality of life was not previously reported.
It was previously unknown whether chemotherapy or surveillance leads to improved outcomes in prostate cancer post-prostatectomy.
COMET-1 and COMET-2 previously showed no overall survival benefit with cabozantinib.
Previous findings suggested that there were no benefits to overall survival or disease-free survival with VEGF-TKIs vs placebo.
This study was designed to evaluate the efficacy of each treatment using 3-year distant metastasis-free survival as a primary outcome.
Patients receiving VEGF-TKIs are likely to have treatment dose reductions, delays, or interruptions because of diarrhea, which occurs in about 50% of cases.
Patients with PRCC1 frequently show MET mutations. Crizotinib, a dual inhibitor of MET and ALK, has shown promising activity in MET-altered cancers.
Seventy-eight patients with metastatic urothelial carcinoma received intravenous nivolumab until disease progression or discontinuation.
The median follow-up was 17.6 months at time of interim analysis.
Of 542 enrolled patients, 270 were randomly assigned to pembrolizumab and 272 were assigned to chemotherapy. All patients progressed after platinum therapy.
Researchers randomly assigned 1401 men with M0 CRPC undergoing ADT to receive enzalutamide 160 mg or placebo.
A significant reduction in prostate cancer-specific mortality — the primary outcome — was observed among patients who received 18 months of AS.
It is unestablished whether daily or weekly IGRT is optimal for patients with N0 localized prostate cancer.
Current screening methods have a low sensitivity for precancerous lesions and are inconvenient, leading to high rates of noncompliance.
Survivors assigned to an experimental arm showed an improvement in the FACT-C functional well-being sub-scale from baseline to 12 weeks.
MEK inhibition with cobimetinib may improve the response rate with checkpoint inhibition.
Researchers treated 74 patients with dMMR/MSI-H mCRC with nivolumab 3 mg/kg every 2 weeks.
Researchers evaluated whether the PD-1 inhibitor would improve outcomes among patients with HCC who progressed after sorafenib treatment.
Researchers randomly assigned 707 patients with advanced HCC to receive oral cabozantinib 60 mg once daily or placebo.
Preclinical models suggested that PEGPH20, which degrades hyaluronan, would improve survival among patients with metastatic pancreatic adenocarcinoma.
The study arms had similar rates of adverse events, with 34.7% of patients in the cisplatin arm and 31.2% of patients in the S-1 arm reporting clinically relevant events.
Robot-assisted minimally invasive thoraco-laparoscopic esophagectomy may be a lower-cost alternative, with better post-operative outcomes, to open transthoracic esophagectomy.
Previous research suggested that EIPL may improve survival by reducing the number of intraperitoneal-free cancer cells.
Investigators evaluated data from 277 patients with gastric cancer, 180 of whom underwent CRS plus HIPEC vs 97 who underwent CRS only.
Researchers evaluated the outcomes of 453 patients with stage I to III esophageal cancer who received definitive or preoperative chemoradiation.
Dr Dreyling, professor of medicine at the University of Munich Hospital, discusses research presented at the 2017 ASH Annual Meeting likely to have a clinical impact among patients with NHL.
The most frequently reported adverse events associated with caplacizumab were epistaxis, gingival bleeding, and bruising.
Nearly 13% of patients in the edoxaban had first recurrent VTE or other major bleeding events during the 12-month follow-up compared with 13.5% of patients in the dalteparin arm.
Patients over the age of 65 years are the most frequently diagnosed group with hematologic cancers, yet these patients are typically under-enrolled in clinical studies evaluating novel therapies.
Researchers investigated whether PET-CT SUV has clinical utility among patients with CLL receiving venetoclax who failed therapy with ibrutinib or idelalisib.
Researchers randomly assigned 389 patients with R/R CLL to VR or BR study arms. Patients were stratified by del(17p) status, responsiveness to previous therapy, and geographic region.
Ongoing clinical trials should clarify optimal axilla management and treatment de-escalation options for patients with normal axillary ultrasound findings after neoadjuvant chemotherapy.
The phase 3 study ASPIRE previously demonstrated that adding carfilzomib to Rd prolongs progression-free survival, though overall survival data were immature.
A relevant prognostic factor for patients with MM is cytogenetic abnormalities, but the effect these abnormalities may have among high-risk transplant-ineligible patients treated with first-line bortezomib or lenalidomide had not previously been investigated.
Among the 60 evaluable patients, the objective response rate was 83%, with CR rate of 62%.
Researchers randomly assigned 1334 patients with untreated stage III or IV HL to receive A + AVD or ABVD for 6 cycles.
This analysis was undertaken to determine whether patient and disease characteristics can predict which patients will benefit from abemaciclib.
The CTS5 model is based on nodal status, tumor size, 3 categories of tumor grade, and age as a continuous variable.
Patients who presented with an MRD level below 10-6 had a significantly improved PFS compared with patients who were above this threshold.
Researchers analyzed the outcomes of 67 patients with BCR-ABL1-positive CML in chronic phase who had an MMR on nilotinib twice daily and who then switched to a once-daily reduced-dose regimen.
Ninety-five percent of patients received elotuzumab at the increased rate of 5 mL/min without any incidence of IR.
Researchers randomly assigned 241 patients to receive radotinib 300 mg twice daily, radotinib 400 mg twice daily, or imatinib 400 mg once daily.
Researchers randomly assigned 597 patients with newly diagnosed AML to receive intermediate- or conventional-dose cytarabine plus homoharringtonine and daunorubicin.
Based on findings from previous studies (COG AALL0031 and EsPhALL 2004-2009), researchers are assessing the association of continuous imatinib plus chemotherapy with the reduced need for HSCT.
At the end of maintenance, 57% and 64% of patients remained in the midostaurin arm or the placebo arm, respectively. There were 16 relapse events after maintenance in the midostaurin arm and 7 relapses and 2 deaths in the placebo arm.
The median time to response (TRR) was 1.9 months. The median duration of response (DoR) was not reached, though the 12-month DoR rate was 72% (95% CI, 62-80%).
Researchers assessed the efficacy of dasatinib — a TKI that is significantly more potent than imatinib and is active even in the setting of imatinib resistance — in this patient population.
At a previously reported median follow-up of 5 years, no DFS difference was detected between patients in the 2 study groups. This analysis was performed after a median follow-up of 9.8 years.
Study findings indicate that margin widths of at least 2 mm are associated with reduced risk of ipsilateral breast failure compared with narrower but uninvolved margins.
Translating these findings into clinical practice will require careful conversations with patients to weigh toxicity and potential benefits for each individual.
Further follow-up should help to clarify the safety and benefits of OFS for late breast cancer OS.
Elevated COX2 levels are associated with breast cancer progression. COX2 is transcriptionally regulated and enhances the aromatase pathway, especially in estrogen receptor-positive tumors.
Patients with stage II to III HER2+ breast cancer underwent tumor biopsy and were then randomly assigned to receive paclitaxel plus trastuzumab alone or with lapatinib for 16 weeks before surgery.
The findings support the use of pCR as a primary endpoint for accelerated approval of new drugs when EFS is evaluated in the relevant patient population.
Patients were randomly assigned to receive fulvestrant, fulvestrant plus continuous daily vistusertib, fulvestrant plus intermittent vistusertib, or fulvestrant plus everolimus.
Long non-coding RNA bound to ESR-1 might contribute to late-stage HR+ breast cancer relapse, researchers reported.
Neither adapted DFS nor OS differed between the groups in multivariate analyses adjusted for patient and tumor variables and chemotherapy.
A total of 159 recurrent CNA regions were identified. ERBB2 amplification was associated with high pCR, but the association fell to insignificance after correcting for ERBB2 expression.
Preclinical studies suggest that radiotherapy's pro-immunogenic effects might improve the antitumor efficacy of immune checkpoint inhibition.
Patients who did not reach a first complete remission were twice as likely to fail rituximab maintenance therapy; patients who received autologous stem cell transplant had a decreased failure risk of 69%.
Ibrutinib is used among patients with WM who have previously received treatment, but its efficacy as a first-line therapy among treatment-naive patients is unknown.
Study results suggest that many patients with multiple myeloma should proceed directly to autologous stem cell transplantation after first-line therapy.
A previous study demonstrated that patients with relapsed MM have a superior PFS and greater depth of response when treated with D-VMP.
Patients received imatinib 300 mg/m2, 400 mg/m2, and 500 mg/m2 for chronic phase, accelerated phase, and blast phase disease, respectively.
Eleven patients had a complete response: 10 had complete cytogenic remission, 8 were negative by flow cytometry, 6 had undetectable BCR-ABL. Three patients did not respond.
Cancer Therapy Advisor asked Shaji Kumar, MD, to share his thoughts about where we are now and where we are going regarding promising data and novel approaches for MM treatment.
Previous analysis of the SWOG S0230/POEMS study suggested that goserelin improves survival rates, ovarian function, and raises the likelihood of pregnancy among patients with hormone receptor-negative disease.
Researchers pooled results from 3 studies, which included 5114 patients with HER2-positive disease, to determine whether 1-year adjuvant trastuzumab yields the optimal OS, DFS, and rate of cardiac events.
Researchers randomly assigned 84 women with HER2-positive breast cancer to receive metformin plus chemotherapy with trastuzumab or chemotherapy with trastuzumab alone.
Metastatic TN and hormone receptor-positive disease is incurable and new therapy options are badly needed.
Complete Resection of Metastatic Soft Tissue Sarcoma Associated With Improved Disease-specific Survival
Researchers attempted to determine factors associated with DSS after patients with metastatic disease undergo surgical resection.
Researchers presented olaratumab monotherapy subgroup results from a phase 2 trial of patients who were previously treated with olaratumab plus doxorubicin or doxorubicin alone.
Just over half of patients in a standard therapy group had normal bone mineral density after a mean follow-up of 6 years; this contrasted with 93% of patients in a vitamin D supplementation group.
Researchers at the Seattle Cancer Care Alliance used email and web screening to determine patient quality of life and psychological comorbidities after a sarcoma diagnosis.
Researchers injected Ewing sarcoma cells into mice to determine the effects of exercise on doxorubicin efficacy and treatment-related cardiotoxicity.
As the disease's location can make localized treatment difficult, factors that predict for LR and OS may be helpful for treatment decision-making.
No significant association between GPNBM levels and disease response was found. Due to futility, the researchers did not pursue a second stage of the trial.
Researchers are evaluating whether BLU-285, which is active regardless of resistance-associated mutations, is safe and effective among patients with an imatinib-resistant GIST.
Researchers enrolled 11 patients with infantile fibrosarcoma or another sarcoma subtype to receive larotrectinib followed by surgery.
In a randomized phase 2 trial, CASPS, researchers enrolled 48 patients with metastatic ASPS that progressed within the preceding 6 months. The primary endpoint was change in tumor size.
Sign Up for Free e-newsletters
Regimen and Drug Listings
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
|Head and Neck Cancer||Regimens||Drugs|
|Renal Cell Carcinoma||Regimens||Drugs|
Cancer Therapy Advisor Articles
- Rectal Cancer: Adjuvant Chemotherapy May Improve OS After pCR
- Breast Cancer: Determining the Best Diet for Disease Prevention
- Hormone Therapy for Breast Cancer May Cause Diabetes
- Post-Oophorectomy Estrogen Therapy May Not Increase Breast Cancer Risk in BRCA1 Carriers
- Carboxyamidotriazole Orotate With Temozolomide May Be Active Against Glioblastoma